Interleukin-6 messenger RNA (IL-6 mRNA)

Interleukin-6 (IL-6) messenger RNA (mRNA) is the genetic template responsible for the production of the IL-6 cytokine, a key mediator of the body's immune and inflammatory responses (UniProt P05231). Under normal physiological conditions, IL-6 mRNA is transiently expressed in response to stimuli like infections or tissue injury to coordinate the acute phase response and stimulate B-cell differentiation (StatPearls, Interleukin-6). However, pathological persistence or overexpression of IL-6 mRNA leads to chronic inflammation and is a major driver of diseases such as rheumatoid arthritis, Castleman disease, and various cancers (PubMed: 26133336). Therapeutic targeting of IL-6 mRNA involves the use of antisense oligonucleotides (ASOs) or RNA interference (RNAi) technologies to selectively bind and degrade the transcript before it can be translated into a functional protein (Ionis Pharmaceuticals, 2018). This upstream intervention aims to provide a more profound or durable suppression of the IL-6 pathway compared to traditional protein-targeting biologics (PubMed: 29439105). While promising, this approach must balance the benefits of inflammation control with the risks of systemic immunosuppression and potential off-target effects associated with oligonucleotide therapies (PubMed: 30216116). Monitoring of downstream biomarkers like C-reactive protein is essential to evaluate the efficacy of mRNA-targeted treatments in clinical settings (PubMed: 28115198).

Other names

IL6 mRNAB-cell stimulatory factor 2 mRNABSF-2 mRNAInterferon beta-2 mRNAIFNB2 mRNAHepatocyte stimulating factor mRNA

Antisense oligonucleotide-mediated degradation of mRNA via RNase H recruitment (Ionis Pharmaceuticals, 2018).